Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases.

[1]  P. Rutgeerts,et al.  The value of serologic markers in indeterminate colitis: a prospective follow-up study. , 2003, Gastroenterology.

[2]  H. Hooijkaas,et al.  Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods , 2002, European journal of gastroenterology & hepatology.

[3]  M. Abreu.  Serologic tests are helpful in managing inflammatory bowel disease , 2002 .

[4]  Y. Shoenfeld,et al.  Serological markers in inflammatory bowel disease: the pros and cons , 2002, European journal of gastroenterology & hepatology.

[5]  A. Šedivá,et al.  Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. , 2002, Clinical immunology.

[6]  M. Daperno,et al.  Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker? , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  A. Zinsmeister,et al.  Evaluation of Serologic Disease Markers in a Population-Based Cohort of Patients with Ulcerative Colitis and Crohn's Disease , 2001, Inflammatory bowel diseases.

[8]  P. Rutgeerts,et al.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[9]  S. Targan,et al.  Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. , 2001 .

[10]  P. Rutgeerts,et al.  Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. , 2001, Gastroenterology.

[11]  A. Maniatis,et al.  Anti–saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[12]  S. Targan,et al.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics , 2000, Gut.

[13]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[14]  Roozendaal,et al.  Are anti‐neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? , 1999, Clinical and experimental immunology.

[15]  W. Sandborn,et al.  Is antibody testing for inflammatory bowel disease clinically useful? , 1999, Gastroenterology.

[16]  P. Banks,et al.  The Role of pANCA and ASCA in Differentiating Ulcerative Colitis, Crohnʼs Disease, and Indeterminate Colitis , 1999 .

[17]  S. Targan.  The utility of ANCA and ASCA in inflammatory bowel disease. , 1999, Inflammatory bowel diseases.

[18]  R. Macdermott.  Lack of current clinical value of serological testing in the evaluation of patients with IBD. , 1999, Inflammatory bowel diseases.

[19]  S. Targan,et al.  Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. , 1998, Gastroenterology.

[20]  P. Rutgeerts,et al.  Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. , 1998, Gastroenterology.

[21]  G. Radford-Smith,et al.  The significance of pANCA in inflammatory bowel disease , 1998, Journal of gastroenterology and hepatology.

[22]  O. Goulet,et al.  Anti-Saccharomyces cerevisiae mannan antibodies in familial crohn’s disease , 1998 .

[23]  S. Targan,et al.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role , 1998, Gut.

[24]  P. Nos,et al.  [Significance of the determination of antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis and Crohn's disease]. , 1998, Gastroenterologia y hepatologia.

[25]  G. Ferry.  The use of antineutrophil cytoplasmic antibodies to determine clinical patterns of ulcerative colitis in children. , 1998, Journal of pediatric gastroenterology and nutrition.

[26]  A. Andriulli,et al.  HLA antigens and pANCA define ulcerative colitis as a genetically heterogeneous disorder. , 1998, Italian journal of gastroenterology and hepatology.

[27]  P. Gionchetti,et al.  Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils. , 1997, Gut.

[28]  S. Targan,et al.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. , 1996, Gastroenterology.

[29]  S. Targan,et al.  Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. , 1996, Mayo Clinic proceedings.

[30]  M. Astegiano,et al.  Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease? , 1995, European journal of gastroenterology & hepatology.

[31]  C. Florén,et al.  Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission. , 1995, European journal of gastroenterology & hepatology.

[32]  S. Targan,et al.  Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. , 1995, The American journal of gastroenterology.

[33]  P. Gionchetti,et al.  p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis , 1994, The Lancet.

[34]  L. Forzenigo,et al.  Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. , 1994, Digestion.

[35]  C. Holdsworth,et al.  Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. , 1992, Gut.

[36]  E. Lindberg,et al.  Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. , 1992, Gut.

[37]  F. Seibold,et al.  Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. , 1992, Gut.

[38]  J. Colombel,et al.  Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. , 1992, Gastroenterologie clinique et biologique.

[39]  S. Targan,et al.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. , 1990, The Journal of allergy and clinical immunology.

[40]  S. Allan,et al.  Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease? , 1990, International archives of allergy and applied immunology.

[41]  M. Kerr,et al.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. , 1988, BMJ.

[42]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[43]  Truelove Sc,et al.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. , 1954 .

[44]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .